DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/x6sbkr/the) has announced the addition of the "The Pharmaceutical Market: Norway" report to their offering.
The macro-environment for the Norwegian pharmaceutical industry is improving. Politically, the centre-left coalition is expected to hold together at least until the general election but the risk of the coalition breaking up has grown. Economically, the recession was far less pronounced in Norway than in most other European countries and economic recovery is now strengthening.
Demographically, the population is ageing, increasing demand for pharmaceuticals in the near term.
The introduction of international reference pricing has had a moderating effect on Norwegian pharmaceutical price levels, and a step-price system for off-patent drugs has ensured that prices for all generics have fallen. Important steps towards cost-containment have also been taken for reimbursable pharmaceuticals, including the use of a first-choice system.
A report by the Business Research Foundation (SNF) has shown that Norwegian pharmaceutical prices are among the lowest in Western Europe. Therefore, market growth is a result of increased consumption, largely due to the ageing population and the introduction of new drugs on the market. Norway is receptive to new drugs, as long as they are cost-effective and have proven therapeutic benefits.
Although Norway is not part of the European Union, the process for pharmaceutical registration has been aligned to EU regulations.
Key Topics Covered:
4. Business Environment
5. Industry Forecast
6. Pharmaceutical Market Forecast
7. Healthcare Market Forecast
9. Pharmaceutical Trade Forecast
10. Macroeconomic Forecasts
11. Economic Analysis
12. Industry Risk Reward Ratings
13. Western Europe Risk/Reward Ratings
14. Norway Risk/Reward Ratings
17. Market Overview
18. Industry Trends And Developments
20. Healthcare Sector
21. Clinical Trials
22. Regulatory Development
23. Pricing Regime
24. Reimbursement Regime
25. Competitive Landscape
26. Demographic Forecast
29. Pharmaceutical Expenditure Forecast Model
30. Healthcare Expenditure Forecast Model
31. Notes On Methodology
32. Risk/Reward Ratings Methodology
33. Ratings Overview
34. Indicator Weightings
For more information visit http://www.researchandmarkets.com/research/x6sbkr/the